Floatz logo

Cladribine

Chronic Progressive Multiple Sclerosis

Queen Mary University of LondonSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Chronic Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
D-Thioctic Acid
Rebecca Spain
Phase 2/3BB
Cyclophosphamide
Bruce Cree
Phase 3BB
Rituximab
Centre Hospitalier de PAU
Phase 2B
Masitinib
AB Science
Phase 3B
Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors
Brainstorm-Cell Therapeutics
Phase 2B

View all 29 →

Same molecule, other indications

Cladribine is also rated in:

relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
76 / 100
View asset →
lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
multiple sclerosisActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →